Extending COTA’s global reach with RWD in oncology research
Cancer is a disease that respects no borders: it affects everyone around the world, no matter where they live. The universal nature of cancer makes it even more important for international partners to collaborate on research and share learnings to improve outcomes everywhere, from the Americas to Europe, Africa to Asia, and beyond. This year, […]
The power of platforms: How data companies can accelerate the use of quality RWD for clinical research
Not all data platforms are created equal, and not all data companies are employing the same techniques to produce reliable and consistent results, notes a recent white paper from the Clinical Research Data Sharing Alliance (CRDSA).
Real world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA)
Amer Methqal Zeidan, Leyla Hernandez Donoso, Sejla Hodzic, Henry F Owusu, Dhrubajyoti Pathak, Summera Qiheng Zhou, Eytan Stein
How to use real world clinicogenomic data to fuel drug development
This blog series talks extensively about the benefits of using real-world data (RWD) to enhance clinical trials and accelerate research into new therapies for a variety of different conditions. Now it s time to take a closer look at the details.
COTA Deloitte On Data Biases
Host Sandy Leonard sits down with experts Laura Fernandes and Sesh Srinivasan to dive into the pressing issue of bias in clinical research.
